PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study — Clara Grazia Chisari (2021) | RDL Network
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study
Jamie Greenfield, Luanne M. Metz, Amir Khakban, Elisabet Rodríguez Llorian, Kristina D. Michaux, Anthony Traboulsee, Jiwon Oh, Penelope Smyth, Larry D. Lynd, Andrew G. M. Bulloch, Jeanne V.A. Williams, Scott Burton Patten
Discussion(0)
No comments yet. Be the first to comment.